James T. England,Natasha Szuber,Shireen Sirhan,Tom Dunne,Sonia Cerquozzi,Madeleine Hill,Pierre J. A. Villeneuve,Jenny M. Ho,Bekim Sadikovic,Pratibha Bhai,Nupur Krishnan,Sebastian Dowhanik,Chris Hillis,Jose-Mario Capo-Chichi,Hubert Tsui,Verna Cheung,Karine Gauthier,Hassan Sibai,Marta B. Davidson,Aniket Bankar,Rouslan Kotchetkov,Vikas Gupta,Dawn Maze

Abstract:Myeloproliferative neoplasms (MPNs) are a group of chronic hematologic malignancies that lead to morbidity and early mortality due to thrombotic complications and progression to acute leukemia. Clinical and mutational risk factors have been demonstrated to predict outcomes in patients with MPNs and are used commonly to guide therapeutic decisions, including allogenic stem cell transplant, in myelofibrosis. Adolescents and young adults (AYA, age ≤45 years) comprise less than 10% of all MPN patients and have unique clinical and therapeutic considerations. The prevalence and clinical impact of somatic mutations implicated in myeloid disease has not been extensively examined in this population. We conducted a retrospective review of patients evaluated at eight Canadian centers for MPN patients diagnosed at ≤45 years of age. In total, 609 patients were included in the study, with median overall survival of 36.8 years. Diagnosis of prefibrotic or overt PMF is associated with the lowest OS and highest risk of AP/BP transformation. Thrombotic complications (24%), including splanchnic circulation thrombosis (9%), were frequent in the cohort. Mutations in addition to those in JAK2/MPL/CALR are uncommon in the initial disease phase in our AYA population (12%); but our data indicate they may be predictive of transformation to post-ET/PV myelofibrosis.

Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study